Carotuximab plus hormone therapy for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called carotuximab given with a standard hormone therapy (apalutamide or enzalutamide) for men with prostate cancer that has stopped responding to current hormone treatments. The goal is to see if this combination can slow the cancer's growth and lower PSA levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer is advanced and your PSA level has been rising while on a standard hormone therapy like abiraterone, enzalutamide, or darolutamide.
- You have had one or two prior hormone therapies (but if you already took enzalutamide, you can only join a specific study arm).
- You are not eligible for or have chosen not to receive chemotherapy (except for docetaxel given when the cancer was hormone-sensitive).
- You have good overall health (ECOG 0-1), meaning you can manage your daily activities.
- Your blood counts, kidney, and liver function are adequate, and any side effects from previous treatments have resolved to acceptable levels.
- You agree to use effective contraception during the study and for 3 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
This trial compares two treatment approaches for advanced prostate cancer that has stopped responding to hormone therapy. One group gets chemotherapy (cabazitaxel with or without carboplatin) and the other gets a targeted radiation therapy (177Lu-PSMA-617). The goal is to see which works better.
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.